Compare LTC Properties Inc (LTC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs State Street SPDR S&P Biotech ETF — how do they compare? LTC Properties Inc trades at $42.53 (market cap $2.27B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.5× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LTC | XBI | |
|---|---|---|
Market Cap | $2.27B | $10.11B |
Volume | 574,171 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $43.50 | $169.55 |
52-Week Low | $33.98 | $104.99 |
Typical Hold Time | 88 Days | 38 Days |
Enterprise Value | $3.01B | — |
Dividend Yield | 5.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.63, up 1.96% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT maintains strong fundamentals with 38.93% net margins and consistent dividend payments of $0.19 monthly. Recent acquisitions totaling $160 million signal aggressive growth in seniors housing properties, though the stock faces resistance near $43.
Outlook remains cautiously optimistic with a $49.67 analyst price target suggesting 16% upside potential. Key opportunities include demographic tailwinds in senior care and portfolio transformation, while risks involve rising interest rates and execution challenges in SHOP segment expansion. The 31.82% buy rating reflects balanced Wall Street sentiment amid transition phase.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
